Cargando…

Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes

IMPORTANCE: Type 2 diabetes (T2D) and heart failure (HF) prevalence are rising in the US. Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes for these conditions, high out-of-pocket costs may be associated with reduced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Essien, Utibe R., Singh, Balvindar, Swabe, Gretchen, Johnson, Amber E., Eberly, Lauren A., Wadhera, Rishi K., Breathett, Khadijah, Vaduganathan, Muthiah, Magnani, Jared W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236237/ https://www.ncbi.nlm.nih.gov/pubmed/37261826 http://dx.doi.org/10.1001/jamanetworkopen.2023.16290

Ejemplares similares

Association of Race and Ethnicity on the Management of Acute Non−ST‐Segment Elevation Myocardial Infarction
por: Tertulien, Tarryn, et al.
Publicado: (2022)

Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019
por: Duvalyan, Angela, et al.
Publicado: (2021)

COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
por: Hernandez, Inmaculada, et al.
Publicado: (2023)

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Separate and Unequal: The Cost of Coronavirus Disease 2019 on Childhood Health and Well-Being
por: Magnani, Jared W., et al.
Publicado: (2021)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Association of income and educational attainment in hospitalization events in atrial fibrillation
por: Tertulien, Tarryn, et al.
Publicado: (2021)

High-Performing and Low-Performing Hospitals Across Medicare Value-Based Payment Programs
por: Khullar, Dhruv, et al.
Publicado: (2022)

Association between income and likelihood of right heart catheterization in individuals with pulmonary hypertension: A US claims database analysis
por: Schikowski, Erin M., et al.
Publicado: (2022)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
por: Schikowski, Erin M., et al.
Publicado: (2022)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022)

Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations
por: Ogunsanmi, Deborah O, et al.
Publicado: (2023)

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Implementation Science to Address Health Disparities During the Coronavirus Pandemic
por: Galaviz, Karla I., et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)

CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
Publicado: (2020)

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Publicado: (2021)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
por: Dey, Amit K., et al.
Publicado: (2019)

Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
por: Kahkoska, Anna R., et al.
Publicado: (2021)

Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
por: Sargeant, Jack Alistair, et al.
Publicado: (2019)

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
por: Hiramatsu, Takeyuki, et al.
Publicado: (2020)

The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
por: Dong, Meiyuan, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
por: Foresta, Andreana, et al.
Publicado: (2023)

Racial and Ethnic Differences in Cardiac Rehabilitation Participation: Effect Modification by Household Income
por: Garfein, Joshua, et al.
Publicado: (2022)

Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention
por: Lapa, Matthew E., et al.
Publicado: (2022)

Association of Fine Particulate Matter and Risk of Stroke in Patients With Atrial Fibrillation
por: Rhinehart, Zachary J., et al.
Publicado: (2020)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
por: Kim, Gwang Sil, et al.
Publicado: (2019)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
por: Adhikari, Rishav, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Prescription Drug Payment Policy: Past, Present, and Future
por: Gondek, Kathleen
Publicado: (1994)

Equity in Heart Transplant Allocation: Intended Progress Up the Hill or an Impossibility?
por: Lewsey, Sabra C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u9c56fe34srglcj4fb48pb8rs1